The Stanford Spin-off Forty Seven Inc.  has a passion for helping cancer patients beat their disease through the development of novel therapies. They began when they discovered an important pathway—CD47-SIRPa—for cancer immune evasion and haven’t stopped since. Their hope is to use this knowledge in developing an antibody (currently called Hu5F9-G4) that will help patients defeat their cancer.  This innovation spin-off will now be collaborating with various other organisations in order to take advantage of what they know to have the most impact possible .
Forty Seven Inc. will focus on combating ovarian cancer with the Bavencio® (avelumab), a Merck/Pfizer product. Together, the companies will hopefully be able to help patients with hard-to-treat cancer, something that is especially common with ovarian cancer patients. 
This academic spin-off will also partner with Genentech Inc. to work on trials involving patients with AML (acute myeloid leukaemia) and bladder cancer . The two trials that they will participate in will combine Forty Seven technologies with a Genentech antibody with the hope that they will be able to help those patients not able to withstand the side-effects of chemotherapy .
Forty Seven Inc. is balancing academic research with market need application in a way that shows their success as an academic spin-off. We can only hope that they are successful in their advancements because what they are working towards could change the way we face cancer.